Literature DB >> 30286415

A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder.

Kelly Perlman1, David Benrimoh2, Sonia Israel3, Colleen Rollins4, Eleanor Brown5, Jingla-Fri Tunteng6, Raymond You7, Eunice You8, Myriam Tanguay-Sela5, Emily Snook9, Marc Miresco10, Marcelo T Berlim3.   

Abstract

INTRODUCTION: The heterogeneity of symptoms and complex etiology of depression pose a significant challenge to the personalization of treatment. Meanwhile, the current application of generic treatment approaches to patients with vastly differing biological and clinical profiles is far from optimal. Here, we conduct a meta-review to identify predictors of response to antidepressant therapy in order to select robust input features for machine learning models of treatment response. These machine learning models will allow us to learn associations between patient features and treatment response which have predictive value at the individual patient level; this learning can be optimized by selecting high-quality input features for the model. While current research is difficult to directly apply to the clinic, machine learning models built using knowledge gleaned from current research may become useful clinical tools.
METHODS: The EMBASE and MEDLINE/PubMed online databases were searched from January 1996 to August 2017, using a combination of MeSH terms and keywords to identify relevant literature reviews. We identified a total of 1909 articles, wherein 199 articles met our inclusion criteria.
RESULTS: An array of genetic, immune, endocrine, neuroimaging, sociodemographic, and symptom-based predictors of treatment response were extracted, varying widely in clinical utility. LIMITATIONS: Due to heterogeneous sample sizes, effect sizes, publication biases, and methodological disparities across reviews, we could not accurately assess the strength and directionality of every predictor.
CONCLUSION: Notwithstanding our cautious interpretation of the results, we have identified a multitude of predictors that can be used to formulate a priori hypotheses regarding the input features for a computational model. We highlight the importance of large-scale research initiatives and clinically accessible biomarkers, as well as the need for replication studies of current findings. In addition, we provide recommendations for future improvement and standardization of research efforts in this field.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30286415     DOI: 10.1016/j.jad.2018.09.067

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  28 in total

1.  Development of Neuroimaging-Based Biomarkers in Major Depression.

Authors:  Kyu-Man Han; Byung-Joo Ham; Yong-Ku Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Predicting treatment outcome in depression: an introduction into current concepts and challenges.

Authors:  Nicolas Rost; Elisabeth B Binder; Tanja M Brückl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-19       Impact factor: 5.270

3.  Proposed protocol for the investigation of the safety and efficacy of the COVID-19 vaccine for patients with psychosis, with pilot safety findings from a Chinese psychiatrist's self-experiment.

Authors:  Chongguang Lin; Tao Fang; Jiayue Chen; Qianchen Li; Weiliang Yang; Cong Yao; Lina Wang; Yun Sun; Ziyao Cai; Jing Ping; Ce Chen; Langlang Cheng; Jinjing Zhu; Guangdong Chen; Peiwei Shan; Chunmian Chen; Xiaodong Lin; Hongjun Tian; Chuanjun Zhuo
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

4.  Creating sparser prediction models of treatment outcome in depression: a proof-of-concept study using simultaneous feature selection and hyperparameter tuning.

Authors:  Nicolas Rost; Tanja M Brückl; Nikolaos Koutsouleris; Elisabeth B Binder; Bertram Müller-Myhsok
Journal:  BMC Med Inform Decis Mak       Date:  2022-07-14       Impact factor: 3.298

5.  Genome-wide association study and polygenic risk score analysis of esketamine treatment response.

Authors:  Qingqin S Li; Ewa Wajs; Rachel Ochs-Ross; Jaskaran Singh; Wayne C Drevets
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

6.  Vasopressin Surrogate Marker Copeptin as a Potential Novel Endocrine Biomarker for Antidepressant Treatment Response in Major Depression: A Pilot Study.

Authors:  Agorastos Agorastos; Anne Sommer; Alexandra Heinig; Klaus Wiedemann; Cüneyt Demiralay
Journal:  Front Psychiatry       Date:  2020-05-20       Impact factor: 4.157

7.  Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data.

Authors:  Dekel Taliaz; Amit Spinrad; Ran Barzilay; Zohar Barnett-Itzhaki; Dana Averbuch; Omri Teltsh; Roy Schurr; Sne Darki-Morag; Bernard Lerer
Journal:  Transl Psychiatry       Date:  2021-07-08       Impact factor: 6.222

8.  Efficacy of hyperbaric oxygen combined with escitalopram in depression and its effect on cognitive function.

Authors:  Kun Mi; Qiang Guo; Bao-Yan Xu; Man Wang; Hao Bi
Journal:  Pak J Med Sci       Date:  2021 Jul-Aug       Impact factor: 1.088

9.  Clinical laboratory tests and five-year incidence of major depressive disorder: a prospective cohort study of 433,890 participants from the UK Biobank.

Authors:  Michael Wainberg; Stefan Kloiber; Breno Diniz; Roger S McIntyre; Daniel Felsky; Shreejoy J Tripathy
Journal:  Transl Psychiatry       Date:  2021-07-07       Impact factor: 6.222

10.  Dynamic Functional Connectivity Predicts Treatment Response to Electroconvulsive Therapy in Major Depressive Disorder.

Authors:  Hossein Dini; Mohammad S E Sendi; Jing Sui; Zening Fu; Randall Espinoza; Katherine L Narr; Shile Qi; Christopher C Abbott; Sanne J H van Rooij; Patricio Riva-Posse; Luis Emilio Bruni; Helen S Mayberg; Vince D Calhoun
Journal:  Front Hum Neurosci       Date:  2021-07-06       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.